$ENSC News

Ensysce Biosciences Enrolls First Patient in Final Phase of PF614-MPAR-102 Clinical Study

Ensysce Biosciences Initiates Final State Of Its PF614-MPAR-102 Clinical Trial To Evaluate Multi-Pill Abuse Resistance Overdose-Protection Technology

Ensysce Biosciences Has Been Granted European Patent Number EP3934635 Titled "COMPOSITIONS COMPRISING ENZYME-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF (FOR THE TREATMENT OR PREVENTION OF ATTENTION DEFICIT DISORDER (ADHD))"

Watching Ensysce Biosciences; Zacks Small-Cap Research Gives Stock $16.45/Share Price Valuation

ENSC Advancing Testing and Expanding Potential

Ensysce Biosciences Reports First Quarter 2026 Financial Results

Ensysce Biosciences Q1 EPS $(0.52) Beats $(0.73) Estimate, Sales $960.999K Miss $1.900M Estimate

Ensysce Biosciences Announces Expansion of Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology

Ensysce Biosciences Announces Receipt Of A Patent For Its Multi-Pill Abuse Resistance Technology From The Taiwan Intellectual Property Office

Ensysce Biosciences CEO Presents at Inaugural Clinical Pain Symposium in Amsterdam

Ensysce Biosciences Secures IRB Approval of Final Phase of PF614-MPAR-102 Clinical Study

Ensysce Biosciences Announces IRB Approval To Initiate Part 3 Of PF614-MPAR-102 Clinical Study, Marking Final Stage In Study Evaluating MPAR Overdose-Protection Technology.

Ensysce Biosciences Secures Second Financing From 2025 Agreement to Advance Breakthrough Pain Programs

Ensysce Biosciences Closes Second Convertible Preferred Stock Financing Of $2M Under Prior Commitment In November 2025 Of Up To $20M Funding Available Over 24 Months

ENSC Making Great Strides Toward Commercialization

Watching Ensysce Biosciences; Zacks Small-Cap Research Gives Stock $16.45 Price Valuation, Says "Earnings Release Show Positive Momentum"

Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results

Ensysce Biosciences Q4 EPS $(0.75) Misses $(0.70) Estimate, Sales $1.882M Beat $500.000K Estimate

Ensysce Biosciences Initiates Live "Ask Me Anything" (AMA) Session Highlighting Growth and Future Plans

Ensysce Biosciences shares are trading lower. The company announced the publication of first clinical manuscript describing its Multi-Pill Abuse Resistance overdose protection technology.